Article
Real-World Evaluation of Factors for Interstitial Lung Disease Incidence and Radiologic Characteristics in Patients With EGFR T790M-positive NSCLC Treated With Osimertinib in Japan.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Dec 2020
Gemma Akihiko, Kusumoto Masahiko, Sakai Fumikazu, Endo Masahiro, Kato Terufumi, Saito Yoshinobu, Baba Tomohisa, Sata Masafumi, Yamaguchi Ou, Yabuki Yutaka, Nogi Yuhiko, Jinushi Masahisa, Sakamoto Kei, Sugeno Masatoshi, Tamura Reiko, Tokimoto Toshimitsu, Ohe Yuichiro
Abstract excerpt
INTRODUCTION: Using real-world Japanese postmarketing data, we characterized interstitial lung disease (ILD) development during the second- or later-line osimertinib treatment for EGFR mutation-positive NSCLC. Retrospective radiologic image evaluation of patients developing ILD was also performed. METHODS: Patients who had ILD events reported as an adverse drug reaction by their physicians and who were assessed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.